Latest chemotherapy Stories
An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine. Researchers from Academia Sinica and the National Taiwan University College of Medicine first identified genes that were involved in cellular invasion, a property of many cancer cells, using the National Cancer Institute's 60 human cancer cell line panel (NCI-60). Comparing the pattern of activation of each of these genes in...
NAPERVILLE, Ill., April 15, 2013 /PRNewswire/ -- George Salti, MD, FACS, renowned surgical oncologist and Associate Professor of Surgery at the University of Illinois at Chicago, has joined the Edward Cancer Center. Dr. Salti will serve as the Co-Medical Director of the Edward Cancer Center and Medical Director of the Edward Hospital Surgical Oncology Program. Dr. Salti uses advanced surgical techniques to treat melanoma, sarcoma, breast cancer, gastrointestinal and esophageal...
Mount Sinai researchers present targets, treatments for prostate, colon, and ovarian cancer at the American Association for Cancer Research Annual Meeting Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting. The meeting took place April 6-10, 2013 in Washington, DC. Natural Product From Soy May Be Effective in...
Company Expands Development Program with Fifth Phase 2 Clinical Trial in the OGX-427 ORCA(TM) Program BOTHELL, Wash. and VANCOUVER, British Columbia, April 11, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small cell lung...
Study Presented at AACR 2013 Examines Bispecific Antibody in Combination with Paclitaxel and Trastuzumab CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was presented as part of the American...
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women. In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of...
New book "The Healing Journey of My Bodacious Ta ta's" explores preventative, holistic options for allowing the body to heal itself Houston, Texas (PRWEB) April 08, 2013 When Venus DeMarco was diagnosed with breast cancer, she sought help from conventional means: doctors and specialists. But after weighing her options, DeMarco realized that she didn’t have to go through surgery, chemotherapy or radiation: the only thing she had to do was change her lifestyle. In her...
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA. "Approximately 20 percent to 40 percent of patients with cancer who receive neurotoxic chemotherapy (e.g., taxanes, platinums, vinca alkaloids, bortezomib) will develop painful chemotherapy-induced peripheral neuropathy. Painful chemotherapy-induced...
In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumors. Specifically, the research team found that introducing genetic material produced by MSCs significantly reduced a particularly resistant form of malignant brain tumor in living lab rats. Detroit, Michigan (PRWEB) April 01, 2013 DETROIT – In a first-of-its-kind...
TOKYO, March 28, 2013 /PRNewswire/ -- Anaeropharma Science Inc. announced on March 28 that it has initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent. About...
Latest chemotherapy Reference Libraries
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
